Clinical trial
Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life Setting
This prospective, open-label, multicenter, observational study will investigate the effectiveness and safety of MabThera SC (rituximab, subcutaneous) induction therapy in patients with non-Hodgkin's lymphoma, following a first initial treat ment of MabThera IV (rituximab, intraveneous). Induction treatment period in the study is estimated to be 8 months.
Category | Value |
---|---|
Study start date | 2014-07-18 |